Novo Nordisk Didn't Crack the U.S. Market. It Outlasted Everyone Who Tried.

In 2022 a word appeared that no marketing department invented: "Ozempic face." Celebrities thinned, a diabetes injection became a cultural event, and the world decided Novo Nordisk had just stormed America. The truth is stranger and far more instructive. The drug behind the frenzy had been FDA-approved since December 5, 2017³ — five years earlier — and the company selling it had been losing the U.S. market for most of a century before that. What looked like a lightning strike was the end of the slowest market-entry campaign in modern pharma.

The official story is that Novo Nordisk cracked the U.S. with Ozempic. It didn't crack anything quickly. After the 1989 merger that created the company, it held roughly 75% of the European insulin market and only about 20% of the American one — and it didn't even mount a serious challenge to Eli Lilly's fast-acting insulin until 2000.⁸ Novo didn't out-execute its way in. It out-survived everyone who tried to do it faster.

Why a company that doesn't answer to a quarter can lose for thirty years and win anyway

Here is the thesis a smart friend can repeat at dinner: Novo Nordisk's real weapon was never a molecule. It was an owner who can't sell and doesn't have to panic. The Novo Nordisk Foundation — a self-governing foundation with no human owners — controls the company through Novo Holdings A/S, which holds about 28% of the share capital but roughly 77% of the votes.⁵ The trick is a dual-class structure: every A share carries 100 votes against 10 for a B share, all the A shares sit with Novo Holdings, and the Foundation's own Articles of Association forbid selling them.⁵ The control is welded shut by charter.

That sounds like governance trivia. It is the entire strategy. A public company that held 20% U.S. share for a decade against a dominant incumbent would face activist investors, a CEO defenestration, a "strategic review," an exit. Novo faced none of it, because the votes that could have forced a retreat were locked in a foundation legally obligated to keep control and to keep spending its winnings on science — roughly DKK 10 billion in grants in 2024 alone.⁶ The structure converts the one thing every rival is short of — time — into a permanent supply. Most companies enter a market on a clock. Novo entered on a calendar measured in decades.

What that patience bought, eventually, was credibility convertible into a new market. Novo had spent a century as the insulin company — trusted by endocrinologists, embedded in clinics, holding device patents on its own delivery pens.⁷ When semaglutide arrived, it didn't enter as a startup begging for a hearing. It entered as the diabetes house extending its franchise. Ozempic's approval rested on the SUSTAIN trial programme, which included a cardiovascular outcomes arm showing a 26% reduction in the primary cardiac endpoint³ — the kind of evidence that turns a metabolic specialist into an evangelist. The insulin reputation was the on-ramp the GLP-1 drugs drove in on.

The slow ramp nobody remembers

Strip away the 2023 hype and the timeline tells a story of grind, not magic. Ozempic was approved for type 2 diabetes in late 2017. Wegovy — the same molecule, dosed for obesity — wasn't approved until June 4, 2021, with the cardiovascular-risk label added in March 2024.⁴ The cultural explosion came a year after that. Five years separated the regulatory green light from the moment the public noticed. The lesson is the inverse of the legend: the win wasn't sudden, it was scheduled — by a company structurally allowed to wait for the schedule to mature.

Isn't this just a foundation getting lucky on a blockbuster?

The fair objection is that patience is a flattering word for hindsight — that Novo didn't win by waiting, it won because semaglutide happened to be a generational drug, and any owner would look brilliant attached to that. There's truth in it. But the structure earns its credit on the downside, not the upside: it is what kept the company in the U.S. game during the twenty years when the bet wasn't paying off, the exact stretch a public rival's board would have used to cut and run. Luck explains the payout. The ownership moat explains why Novo was still standing at the table to collect it.

There's a second, sharper objection: that the moat isn't innovation at all, it's a barricade. A peer-reviewed study found that barriers to biosimilar insulin competition in the U.S. were driven not by surviving compound patents but by device patents and the structural power of the Big Three oligopoly of Novo, Sanofi, and Eli Lilly — a finding that predated the FDA's 2021 approval of the first biosimilar insulins and explains why that market opened so late.⁷ That is a regulatory moat, and it's under political pressure. The GLP-1 era rhymes with it: critics count 320 patent applications filed on the three semaglutide drugs, with the core patent stretched toward 2031 and a thicket of minor modifications claiming protection through 2042.¹¹ A patient long-term builder and an aggressive patent fortress can be the same company. They are.

And that moment has arrived. Novo's branded GLP-1 obesity volume share was 59.6% as of its 2025 Annual Report — a lead, but not the rout the headlines imply, and it is shrinking as Lilly's tirzepatide gains.²¹³ In December 2025 Novo did finally land the first oral GLP-1 approved specifically for weight loss, oral Wegovy.¹² Yet even that didn't reassure the market that built the company: its shares fell 10.6% in 2024, and Novo Holdings reported a -46.6% return on its Novo Nordisk stake in 2025.¹² The foundation that could never be forced to sell is now sitting on a loss it cannot trade out of.

That is the closing irony of the whole hundred-year campaign. The structure that let Novo Nordisk lose patiently for thirty years and win is the same structure that now forces it to hold its position no matter how fast the ground shifts beneath it. Patience built the empire on a calendar. Its rival is fighting on a clock. The company that out-waited everyone has finally met an opponent it can't outlast — only outrun.